[go: up one dir, main page]

EP1487965A4 - Minicell compositions and methods - Google Patents

Minicell compositions and methods

Info

Publication number
EP1487965A4
EP1487965A4 EP02747872A EP02747872A EP1487965A4 EP 1487965 A4 EP1487965 A4 EP 1487965A4 EP 02747872 A EP02747872 A EP 02747872A EP 02747872 A EP02747872 A EP 02747872A EP 1487965 A4 EP1487965 A4 EP 1487965A4
Authority
EP
European Patent Office
Prior art keywords
methods
minicell compositions
minicell
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02747872A
Other languages
German (de)
French (fr)
Other versions
EP1487965A2 (en
Inventor
Roger A Sabbadini
Mark Surber
Neil Berkley
Matthew Giacalone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxiion Therapeutics LLC
Original Assignee
Mpex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1487965(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/154,951 external-priority patent/US20030194798A1/en
Application filed by Mpex Pharmaceuticals Inc filed Critical Mpex Pharmaceuticals Inc
Priority to EP20110000796 priority Critical patent/EP2390308A1/en
Priority to EP10008869.9A priority patent/EP2272946B9/en
Publication of EP1487965A2 publication Critical patent/EP1487965A2/en
Publication of EP1487965A4 publication Critical patent/EP1487965A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP02747872A 2002-02-25 2002-05-28 Minicell compositions and methods Withdrawn EP1487965A4 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP20110000796 EP2390308A1 (en) 2002-02-25 2002-05-28 Minicell compositions and methods
EP10008869.9A EP2272946B9 (en) 2002-02-25 2002-05-28 Minicell compositions and methods

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US154951 1988-02-10
US35984302P 2002-02-25 2002-02-25
US359843P 2002-02-25
US10/154,951 US20030194798A1 (en) 2001-05-24 2002-05-24 Minicell compositions and methods
PCT/US2002/016877 WO2003072014A2 (en) 2002-02-25 2002-05-28 Minicell compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP10008869.9A Division EP2272946B9 (en) 2002-02-25 2002-05-28 Minicell compositions and methods

Publications (2)

Publication Number Publication Date
EP1487965A2 EP1487965A2 (en) 2004-12-22
EP1487965A4 true EP1487965A4 (en) 2006-11-15

Family

ID=27767433

Family Applications (3)

Application Number Title Priority Date Filing Date
EP10008869.9A Revoked EP2272946B9 (en) 2002-02-25 2002-05-28 Minicell compositions and methods
EP02747872A Withdrawn EP1487965A4 (en) 2002-02-25 2002-05-28 Minicell compositions and methods
EP20110000796 Withdrawn EP2390308A1 (en) 2002-02-25 2002-05-28 Minicell compositions and methods

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10008869.9A Revoked EP2272946B9 (en) 2002-02-25 2002-05-28 Minicell compositions and methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20110000796 Withdrawn EP2390308A1 (en) 2002-02-25 2002-05-28 Minicell compositions and methods

Country Status (5)

Country Link
EP (3) EP2272946B9 (en)
AU (1) AU2002318168B2 (en)
CA (1) CA2517027A1 (en)
ES (1) ES2541351T3 (en)
WO (1) WO2003072014A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7117033B2 (en) 2000-05-08 2006-10-03 Brainsgate, Ltd. Stimulation for acute conditions
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US7396822B2 (en) 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
WO2003033519A2 (en) * 2001-10-15 2003-04-24 Engeneic Gene Therapy Pty Limited Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo
US7561919B2 (en) 2002-11-14 2009-07-14 Brainsgate Ltd. SPG stimulation via the greater palatine canal
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
CA2549840C (en) 2003-12-09 2012-03-20 Engeneic Molecular Delivery Pty Ltd. Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
US8772013B2 (en) 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
SI1718338T1 (en) 2004-02-02 2015-09-30 Engeneic Molecular Delivery Pty Ltd. Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
JP4114075B2 (en) * 2004-02-16 2008-07-09 ヒューマン・メタボローム・テクノロジーズ株式会社 Method for identifying function of gene product and method for identifying binding substance
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8010189B2 (en) 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US20060002956A1 (en) * 2004-04-05 2006-01-05 Surber Mark W Minicells as vaccines
MX2007002294A (en) 2004-08-26 2007-10-19 Engeneic Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells.
PL2040725T3 (en) 2006-06-23 2014-08-29 Engeneic Molecular Delivery Pty Ltd Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
ES2720659T3 (en) 2011-02-15 2019-07-23 Vaxiion Therapeutics Llc Therapeutic compositions and methods for the directed administration, by means of bacterial mini-cells, of bioactive molecules based on targeted molecules containing Fc and antibodies
US20140342932A1 (en) * 2011-09-23 2014-11-20 Merck Sharp & Dohme Corp. Functional cell surface display of ligands for the insulin and/or insulin growth factor 1 receptor and applications thereof
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
RU2577138C1 (en) * 2014-11-25 2016-03-10 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Method of producing of recombinant protein sav-rgd
EP3093043B1 (en) 2015-05-13 2018-11-14 Brainsgate Ltd. Implant and delivery system for neural stimulator
CN110546250A (en) 2017-04-28 2019-12-06 农业球体公司 Compositions and methods for encapsulation and scalable delivery of agrochemicals
MX2020003074A (en) 2017-09-25 2020-09-14 Agrospheres Inc Compositions and methods for scalable production and delivery of biologicals.
TW202012616A (en) 2018-09-28 2020-04-01 日商住友化學股份有限公司 Microorganism preparation for decomposing bacteria, target microorganisms, decomposition method of target microorganisms, decomposition device of target microorganisms
SG11202107306WA (en) 2019-01-04 2021-08-30 Engeneic Molecular Delivery Pty Ltd Encapsulated glycolipid antigens for treatment of neoplastic diseases
CN110669811A (en) * 2019-10-21 2020-01-10 天津大学 Method for improving surfactant yield
MX2022010917A (en) * 2020-03-06 2022-11-30 Endolytix Tech Inc Compositions and methods for the treatment of intracellular bacterial infections.
CN116087504B (en) * 2023-02-24 2023-08-15 上海碧云天生物技术有限公司 Immune magnetic bead protection liquid, preparation method and application thereof
CN119689002B (en) * 2025-02-25 2025-06-06 山东大学 Biomarker combination for predicting embryo repeated planting failure, kit and application thereof, and combined medicine and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033519A2 (en) * 2001-10-15 2003-04-24 Engeneic Gene Therapy Pty Limited Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132769A (en) 1974-10-30 1979-01-02 Osther Kurt B Cancer antigen, cancer therapy, and cancer diagnosis
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US5212071A (en) 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US4190495A (en) 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
US4311797A (en) 1979-09-18 1982-01-19 University Of Saskatchewan Anucleated live E. coli vaccine
US4497796A (en) 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
US4895724A (en) 1985-06-07 1990-01-23 Pfizer Inc. Chitosan compositions for controlled and prolonged release of macromolecules
US4839293A (en) 1986-02-24 1989-06-13 The Trustees Of Columbia University In The City Of New York DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US4921790A (en) 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
US5654176A (en) 1987-05-28 1997-08-05 Amrad Corporation Limited Fusion proteins containing glutathione-s-transferase
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5053489A (en) 1988-01-29 1991-10-01 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4914021A (en) 1988-03-04 1990-04-03 New England Deaconess Hospital Corporation Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US6307030B1 (en) 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
ATE197067T1 (en) 1989-04-07 2000-11-15 Cancerforskningsfonden Af 1989 UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR
US6261800B1 (en) 1989-05-05 2001-07-17 Genentech, Inc. Luteinizing hormone/choriogonadotropin (LH/CG) receptor
US5260432A (en) 1989-06-22 1993-11-09 Sloan-Kettering Institute For Cancer Research Human gamma retinoic acid receptor DNA
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5652122A (en) 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5773024A (en) 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
JP3949711B2 (en) 1990-02-26 2007-07-25 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ Identification and expression of insect steroid receptor DNA sequences
EP0475292B1 (en) 1990-09-10 1999-06-30 Takeda Chemical Industries, Ltd. Human luteinizing hormone-human chorionic gonadotropin receptor (Human LH/hCG receptor)
US5314695A (en) 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
JP3050424B2 (en) 1991-07-12 2000-06-12 塩野義製薬株式会社 Human endothelin receptor
US6027725A (en) 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
GB2265375A (en) 1992-03-16 1993-09-29 Merck & Co Inc Human nuerokinin-3 receptor
US6225080B1 (en) 1992-03-23 2001-05-01 George R. Uhl Mu-subtype opioid receptor
US5532347A (en) 1992-04-10 1996-07-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization DNA encoding α melanocyte stimulating hormone receptor
US5837521A (en) 1993-04-08 1998-11-17 State Of Oregon Nucleic acids encoding the γ-MSH receptor MC3-R
US6313279B1 (en) 1992-05-01 2001-11-06 Eli Lilly And Company Human glutamate receptor and related DNA compounds
FR2692592B1 (en) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc DNA fragments encoding the Neisseria meningitidis transferrin receptor subunits and methods of expressing them.
JP4208960B2 (en) 1992-08-13 2009-01-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Opioid receptor gene
US6300087B1 (en) 1992-11-03 2001-10-09 Synaptic Pharmaceutical Corporation DNA encoding a human serotonin receptor (5-HT4B) and uses thereof
CA2149889A1 (en) 1992-11-20 1994-06-09 Ralph C. Dornburg Cell-type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins
WO1994018562A1 (en) 1993-02-05 1994-08-18 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
US6258556B1 (en) 1993-02-26 2001-07-10 The United States Of America As Represented By The Department Of Health And Human Services cDNA and genomic clones encoding human μ opiate receptor and the purified gene product
US6235496B1 (en) 1993-03-08 2001-05-22 Advanced Research & Technology Institute Nucleic acid encoding mammalian mu opioid receptor
GB2286188B (en) 1993-04-20 1997-11-12 Salk Inst Biotech Ind Human N-methyl-D-aspartate receptor subunits,nucleic acids encoding same and uses therefor
US5763575A (en) 1993-07-26 1998-06-09 Cor Therapeutics, Inc. Agonist and antagonist peptides of the C140 receptor
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
FI961251A0 (en) 1993-09-20 1996-03-18 Ciba Geigy Human metabotropic glutamate receptor subtypes (HMR4, HMR6, HMR7) and to these related DNA compounds
DE69434839T2 (en) 1993-11-08 2007-10-25 Sanofi Pasteur Ltd., Toronto TRANSFERRINE RECEPTOR GENES FROM HAEMOPHILUS
US6248554B1 (en) 1993-11-24 2001-06-19 The Procter & Gamble Company DNA sequence coding for a BMP receptor
US6225531B1 (en) 1994-06-17 2001-05-01 Kirin Beer Kabushiki Kaisha Glucan elicitor receptor, DNA molecule coding therefor, fungus-resistant plants transformed with the DNA molecule and method for creating the plants
GB9416536D0 (en) 1994-08-16 1994-10-12 Karobio Ab Orphan receptor
JP3949715B2 (en) 1994-09-05 2007-07-25 アムラド・オペレイションズ・プロプライエタリー・リミテッド Novel hemopoietin receptor
US6306622B1 (en) 1994-11-04 2001-10-23 The Procter & Gamble Co. cDNA encoding a BMP type II receptor
US6245893B1 (en) 1994-12-17 2001-06-12 Smithkline Beecham P.L.C. Receptor that binds anti-convulsant compounds
JP3064015B2 (en) 1995-01-26 2000-07-12 メルク フロスト カナダ アンド カンパニー Prostaglandin receptor DP
US6111079A (en) 1995-06-05 2000-08-29 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefore
US6025191A (en) 1995-06-07 2000-02-15 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof
US6291207B1 (en) 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6017721A (en) 1995-10-18 2000-01-25 The United States Of America As Represented By The Department Of Health And Human Services Chromatographic method and device for preparing blood serum for compatibility testing
US6048539A (en) 1995-11-02 2000-04-11 Connaught Laboratories Limited Lactoferrin receptor protein
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
US6268214B1 (en) 1996-04-04 2001-07-31 Roche Diagnostics Gmbh Vectors encoding a modified low affinity nerve growth factor receptor
US5965392A (en) 1996-04-08 1999-10-12 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
US6271347B1 (en) 1996-04-26 2001-08-07 Merck & Co., Inc. Eosinophil eotaxin receptor
US6258944B1 (en) 1996-05-06 2001-07-10 Merck & Co., Inc. OB receptor isoforms and nucleic acids encoding them
WO1998011221A2 (en) 1996-09-13 1998-03-19 Dana-Farber Cancer Institute Car, a novel coxsackievirus and adenovirus receptor
JP2001508293A (en) 1996-12-27 2001-06-26 メルク エンド カンパニー インコーポレーテッド Mouse galanin receptor GALR2 and nucleotides encoding the receptor
ATE321855T1 (en) 1997-01-14 2006-04-15 Human Genome Sciences Inc TUMOR NECROSIS FACTOR RECEPTOR 5
US6017735A (en) 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US6242251B1 (en) 1997-03-18 2001-06-05 Eli Lilly And Company Rhesus neuropeptide Y5 receptor
AU6769998A (en) 1997-03-26 1998-10-20 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
JP3885177B2 (en) 1997-03-26 2007-02-21 大塚製薬株式会社 Human gene
US5951951A (en) 1997-04-30 1999-09-14 Medtronic, Inc. Platelet function evaluation technique for citrated whole blood
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
DE69819345T2 (en) 1997-08-20 2004-07-15 The Regents Of The University Of California, Oakland NUCLEIC ACID SEQUENCES ENCODING THE CAPSAICIN RECEPTOR AND POLYPEPTIDES SIMILAR TO THE CAPSAICIN RECEPTOR AND THEIR USE
US6222015B1 (en) 1997-09-08 2001-04-24 Merck & Co., Inc. Estrogen receptor
ATE362983T1 (en) 1997-11-11 2007-06-15 Ono Pharmaceutical Co HUMAN LYSOPHOSPHATIDIC ACID RECEPTOR AND USE THEREOF
US6210967B1 (en) 1997-12-10 2001-04-03 Synaptic Pharmaceutical Corporation DNA encoding a mammalian LPA receptor and uses thereof
DE69941187D1 (en) 1998-06-01 2009-09-10 Agensys Inc SERPENTINTRANSMEMBRANANTIGENE EXPRESSED IN HUMAN CANCER AND ITS USES
US6248520B1 (en) 1998-07-06 2001-06-19 The Rockefeller University Nucleic acid molecules encoding nuclear hormone receptor coactivators and uses thereof
US6221613B1 (en) 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
US7125679B2 (en) 2001-03-07 2006-10-24 Children's Medical Center Corporation Methods to screen peptide libraries using minicell display
US20030166099A1 (en) * 2001-06-05 2003-09-04 Sabbadini Roger A. Minicells comprising membrane proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033519A2 (en) * 2001-10-15 2003-04-24 Engeneic Gene Therapy Pty Limited Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GIACALONE ET AL: "Immune responses elicited by bacterial minicells capable of simultaneous DNA and protein antigen delivery", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 24, no. 33-34, 14 August 2006 (2006-08-14), pages 6009 - 6017, XP005571294, ISSN: 0264-410X *
KHACHATOURIANS G G: "MINICELLS AS SPECIALIZED VACCINES AND VACCINE CARRIERS", ISAACSON, R. E. (ED.). RECOMBINANT DNA VACCINES: RATIONALE AND STRATEGY. XV+409P. MARCEL DEKKER, INC.: NEW YORK, NEW YORK, USA; BASEL, SWITZERLAND. ILLUS, 1992, pages 323 - 333, XP009072825, ISSN: 0-8247-8699-8 *
SUZUKI M ET AL: "PRODUCTION IN ESCHERICHIA-COLI OF BIOLOGICALLY ACTIVE SECRETIN A GASTRO INTESTINAL HORMONE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 79, no. 8, 1982, pages 2475 - 2479, XP002400466, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2003072014B1 (en) 2004-04-22
ES2541351T3 (en) 2015-07-17
HK1153229A1 (en) 2012-03-23
EP2272946B1 (en) 2015-04-08
EP2390308A1 (en) 2011-11-30
EP2272946B9 (en) 2015-06-24
AU2002318168B2 (en) 2007-12-13
WO2003072014A2 (en) 2003-09-04
EP2272946A3 (en) 2011-07-27
WO2003072014A3 (en) 2004-02-12
AU2002318168A1 (en) 2003-09-09
EP1487965A2 (en) 2004-12-22
CA2517027A1 (en) 2003-09-04
EP2272946A2 (en) 2011-01-12

Similar Documents

Publication Publication Date Title
EP1487965A4 (en) Minicell compositions and methods
GB0411940D0 (en) Methods and compositions
EP1701725A4 (en) Methods and compositions
AU2002357119A8 (en) Mitocidal compositions and methods
EP1539941A4 (en) Adzymes and uses thereof
GB0222091D0 (en) Dental compositions and methods
AU2003256805A8 (en) Compounds compositions and methods
GB0208081D0 (en) Skincare compositions and methods
AU2003275268A8 (en) Hemostatic compositions and methods
AU2003297595A8 (en) Atm kinase compositions and methods
EP1684771A4 (en) Composition and method
GB0202059D0 (en) Chemical compositions and methods
AU2002357748A8 (en) Osteopontin-related compositions and methods
AU2003213120A8 (en) Human rnase iii and compositions and uses thereof
EP1539191A4 (en) Glycoalkaloid compositions and various uses thereof
AU2002366809A8 (en) Syn3 compositions and methods
EP1583557A4 (en) Vaccine compositions and methods
GB2384705B (en) Cosmetic and related compositions
AU2003231827A8 (en) Pseudo-tissues and uses thereof
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
GB0207224D0 (en) Tenascin-W compositions and uses thereof
GB0325942D0 (en) Compositions and uses thereof
AU2003245524A8 (en) Cryosurgery compositions and methods
AU2002359869A8 (en) Pak5-related compositions and methods
AU2003216442A8 (en) Enkurin and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040922

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MPEX PHARMACEUTICALS, INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BERKLEY, NEIL

Inventor name: GIACALONE, MATTHEW

Inventor name: SABBADINI, ROGER, A.

Inventor name: SURBER, MARK

A4 Supplementary search report drawn up and despatched

Effective date: 20061013

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VAXIION THERAPEUTICS INC

17Q First examination report despatched

Effective date: 20090209

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VAXIION THERAPEUTICS, LLC

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/66 20060101ALI20160714BHEP

Ipc: C12N 1/00 20060101AFI20160714BHEP

Ipc: A61K 48/00 20060101ALI20160714BHEP

Ipc: A61K 9/48 20060101ALI20160714BHEP

Ipc: C12N 15/70 20060101ALI20160714BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160825

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20170206

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170617